Compare MHK & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHK | BLCO |
|---|---|---|
| Founded | 1988 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.0B |
| IPO Year | 1992 | 2022 |
| Metric | MHK | BLCO |
|---|---|---|
| Price | $135.45 | $17.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 13 |
| Target Price | ★ $131.00 | $17.25 |
| AVG Volume (30 Days) | ★ 790.9K | 307.3K |
| Earning Date | 02-12-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.93 | N/A |
| Revenue | ★ $10,785,400,000.00 | $4,976,000,000.00 |
| Revenue This Year | $0.34 | $8.06 |
| Revenue Next Year | $2.24 | $5.81 |
| P/E Ratio | $22.51 | ★ N/A |
| Revenue Growth | N/A | ★ 6.23 |
| 52 Week Low | $96.24 | $10.45 |
| 52 Week High | $143.13 | $17.86 |
| Indicator | MHK | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 70.73 | 49.54 |
| Support Level | $132.05 | $16.60 |
| Resistance Level | $137.85 | $17.45 |
| Average True Range (ATR) | 3.93 | 0.45 |
| MACD | 0.89 | 0.01 |
| Stochastic Oscillator | 90.95 | 53.12 |
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Geographically, it derives a majority of its revenue from the United States, while it also operates in Latin America, Europe and Others.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.